Installation of the first XPS™ in Asia
Medcor LLP has purchased an XVIVO Perfusion System (XPS™). Medcor will cooperate in the establishment of a new clinical program for lung transplantation and Ex Vivo Lung Perfusion (EVLP) in Almaty, Kazakhstan. This is the first XPS™ sold in Asia.
Strategic collaborations between University Hospitals in Kazakhstan with prestigious Universities in the U.S. and Europe have resulted in unique collaborations to improve health care quality through exchange of knowledge and skills in a variety of areas, including lung transplantation. Lung transplantation is the only therapeutic option for selected patients suffering from end stage lung diseases. Earlier this year, Kazakhstan Vice-Minister of Healthcare Erik Baizhunussov, announced that the first lung transplantation will be made in Kazakhstan in 2014.
“We are ready for this type of transplantation. There are many patients who need this surgery as no other kind of surgery can save them. I think that we will be able to begin this surgery in 2014,” said Mr Baizhunussov.
At present, Asia accounts for less than five percent of the total number of lung transplants carried out in the world, but with increased economic opportunities, the number of lung transplants may increase. In instituting the STEEN Solution™ method with XPS™ early in these markets, this development can occur more rapidly than would otherwise be possible.
“It is a great pleasure to note that the XPS™ will be used to support the establishment of a new clinical program for lung transplantation in Asia. This is a great step forward to establish EVLP throughout the globe”, says Mr Christer de Flon, Marketing & Sales Director, XVIVO Perfusion.
September 30, 2014
Gothenburg
XVIVO Perfusion AB (publ)
Magnus Nilsson
CEO
For further information please contact:
Christoffer Rosenblad, CFO, +46 31 788 21 59, christoffer.rosenblad@xvivoperfusion.com
For further information on XVIVO Perfusion’s business, please refer to the company’s website, www.xvivoperfusion.com
The information was submitted for publication on September 30, 2014 at 2:30 p.m.
This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.
______________________________________________________________________________________________________________________
XVIVO Perfusion AB is a medical technology company which develops solutions and systems for assessing and preserving organs outside the body and for selecting usable organs and maintaining them in optimal condition pending transplantation.
The company is headquartered in Gothenburg, Sweden, and has one office in the USA. The XVIVO share is listed on NASDAQ OMX First North and has the ticker symbol XVIVO. More information can be found on the website www.xvivoperfusion.com. The Certified Adviser is Redeye, www.redeye.se.
______________________________________________________________________________________________________________________
XVIVO Perfusion AB (publ), Box 53015, SE-400 14 Göteborg. Corporate identity number 556561-0424.
Tel: 46 31 788 21 50. Fax: 46 31 788 21 69.
E-mail: info@xvivoperfusion.com. Website: www.xvivoperfusion.com
Tags: